Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)

NCT07521046 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

15

Enrollment

OTHER

Sponsor class

Conditions

Myelofibrosis

Interventions

DRUG: ropeginterferon alfa- 2b
DRUG: Ruxolitinib

Sponsor

University of Utah

Collaborators

[object Object]